Discrepant Antigen-specific Antibody Responses Causing SARS-CoV-2 Persistence in a Patient Receiving B-cell-targeted Therapy with Rituximab

A 73-year-old man previously treated with rituximab for his mucosa-associated lymphoid tissue lymphoma suffered a suboptimal humoral immune response against an acquired SARS-CoV-2 infection. A detailed serological description revealed discrepant antigen-specific humoral immune responses. The titer o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Internal Medicine 2021/12/01, Vol.60(23), pp.3827-3831
Hauptverfasser:	Takakuwa, Teruhito, Nakagama, Yu, Yasugi, Mayo, Maeda, Toshiki, Matsuo, Kenji, Kiritoshi, Ayako, Deguchi, Ryo, Hagawa, Naohiro, Shibata, Wataru, Oshima, Kazuhiro, Yamamoto, Katsumi, Uchida, Kenichiro, Noda, Tomohiro, Yamada, Koichi, Nishimura, Tetsuro, Yamamoto, Hiromasa, Kido, Yasutoshi, Hino, Masayuki, Kakeya, Hiroshi, Mizobata, Yasumitsu
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antibodies Antibodies, Viral Antibody Formation Antibody response Antigens Case Report COVID-19 Humans Immune clearance Immune response (humoral) Internal medicine Lymphocytes B Lymphoma Male Mucosa Mucosal-associated lymphoid tissue neutralizing activity Nucleocapsids persistent RNAemia Rituximab Rituximab - therapeutic use SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Spike Glycoprotein, Coronavirus
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!